KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Range Low Price High Price Comment
30 days $13.11 $17.90 Friday, 26th Apr 2024 SRRK stock ended at $14.53. This is 4.08% more than the trading day before Thursday, 25th Apr 2024. During the day the stock fluctuated 5.94% from a day low at $13.88 to a day high of $14.71.
90 days $12.81 $17.90
52 weeks $5.56 $21.17

Historical Scholar Rock Holding Corp. prices

Date Open High Low Close Volume
Apr 26, 2024 $14.05 $14.71 $13.88 $14.53 473 359
Apr 25, 2024 $13.60 $14.17 $13.60 $13.96 827 578
Apr 24, 2024 $14.83 $14.94 $14.01 $14.09 408 251
Apr 23, 2024 $14.11 $15.13 $14.03 $14.79 735 273
Apr 22, 2024 $14.11 $14.32 $13.79 $14.00 824 580
Apr 19, 2024 $13.94 $14.20 $13.18 $13.85 689 578
Apr 18, 2024 $13.70 $14.08 $13.50 $13.95 668 939
Apr 17, 2024 $14.02 $14.26 $13.41 $13.70 718 777
Apr 16, 2024 $13.20 $14.05 $13.15 $14.00 382 819
Apr 15, 2024 $13.45 $13.57 $13.11 $13.33 482 921
Apr 12, 2024 $13.99 $14.86 $13.20 $13.45 505 070
Apr 11, 2024 $14.20 $14.46 $13.92 $14.17 340 785
Apr 10, 2024 $14.13 $14.58 $13.69 $14.02 536 950
Apr 09, 2024 $14.50 $14.86 $14.34 $14.82 341 467
Apr 08, 2024 $14.40 $14.69 $14.24 $14.50 402 650
Apr 05, 2024 $14.25 $14.64 $13.93 $14.39 480 772
Apr 04, 2024 $15.32 $15.80 $14.36 $14.40 551 028
Apr 03, 2024 $15.65 $15.95 $14.93 $15.23 650 343
Apr 02, 2024 $16.26 $16.73 $15.55 $15.72 724 207
Apr 01, 2024 $17.60 $17.65 $16.35 $16.79 881 554
Mar 28, 2024 $17.19 $17.90 $15.27 $17.76 1 749 804
Mar 27, 2024 $15.16 $15.54 $15.13 $15.45 582 382
Mar 26, 2024 $16.23 $16.43 $14.92 $15.00 1 027 358
Mar 25, 2024 $16.18 $16.94 $15.73 $16.01 632 043
Mar 22, 2024 $17.11 $17.35 $16.31 $16.39 801 512
Click to get the best stock tips daily for free!

About Scholar Rock Holding Corp.

Scholar Rock Holding . Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical tria... SRRK Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT